Selumetinib

Experimental drug selumetinib benefits patients with metastatic uveal melanoma

By

The new drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new research.

Study drug is first to help patients with recurrent low-grade ovarian cancer

By

A phase II clinical trial provides the first evidence of a relatively high response rate in patients with low-grade serous ovarian cancer receiving the drug selumetinib.

First success of targeted therapy in common genetic subtype of NSCLC

By

A new study is the first to demonstrate that the combination of chemotherapy and selumetinib, a new targeted therapy, works better than chemotherapy alone in treating patients with a common genetic subtype of NSCLC.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs